Vor Biopharma Statistics

Total Valuation

Vor Biopharma has a market cap or net worth of $255.81 million. The enterprise value is $55.25 million.

Market Cap	255.81M
Enterprise Value	55.25M

Important Dates

The last earnings date was Tuesday, August 12, 2025, after market close.

Earnings Date	Aug 12, 2025
Ex-Dividend Date	n/a

Share Statistics

Vor Biopharma has 126.64 million shares outstanding. The number of shares has increased by 42.97% in one year.

Current Share Class	126.64M
Shares Outstanding	126.64M
Shares Change (YoY)	+42.97%
Shares Change (QoQ)	+0.36%
Owned by Insiders (%)	31.13%
Owned by Institutions (%)	11.29%
Float	47.57M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.49

Current Ratio	3.49
Quick Ratio	3.41
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-132.36%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-250.62%
Revenue Per Employee	n/a
Profits Per Employee	-$10.47M
Employee Count	159
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +146.55% in the last 52 weeks. The beta is 2.06, so Vor Biopharma's price volatility has been higher than the market average.

Beta (5Y)	2.06
52-Week Price Change	+146.55%
50-Day Moving Average	1.48
200-Day Moving Average	1.04
Relative Strength Index (RSI)	52.30
Average Volume (20 Days)	5,759,972

Short Selling Information

The latest short interest is 18.57 million, so 14.66% of the outstanding shares have been sold short.

Short Interest	18.57M
Short Previous Month	14.38M
Short % of Shares Out	14.66%
Short % of Float	39.04%
Short Ratio (days to cover)	1.13

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-367.40M
Pretax Income	-118.09M
Net Income	-1.66B
EBITDA	-362.82M
EBIT	-367.40M
Earnings Per Share (EPS)	-$17.13

Full Income Statement

Balance Sheet

The company has $200.57 million in cash and n/a in debt, giving a net cash position of $200.57 million or $1.58 per share.

Cash & Cash Equivalents	200.57M
Total Debt	n/a
Net Cash	200.57M
Net Cash Per Share	$1.58
Equity (Book Value)	-1.51B
Book Value Per Share	-11.98
Working Capital	146.15M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$113.60 million and capital expenditures -$489,000, giving a free cash flow of -$114.09 million.

Operating Cash Flow	-113.60M
Capital Expenditures	-489,000
Free Cash Flow	-114.09M
FCF Per Share	-$0.90

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Vor Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-42.97%
Shareholder Yield	-42.97%
Earnings Yield	-650.64%
FCF Yield	-44.60%

Analyst Forecast

The average price target for Vor Biopharma is $3.77, which is 86.63% higher than the current price. The consensus rating is "Buy".

Price Target	$3.77
Price Target Difference	86.63%
Analyst Consensus	Buy
Analyst Count	7
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1